Company: ARAI
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023999
Chunk: 2

Company: Arrive AI Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 2
---
 a reliable, chain-of-custody compliant hub for the drop-off and pickup of
biospecimens from the cancer center. The first deployment installed two third generation Arrive Points (“AP3”) in conjunction
with ground robots in a single route. Initial revenue was recorded in this quarter for the engineering, development and consulting on
the project. Recurring subscription service for access to the Arrive network and rolling robots began in August 2025. Additional delivery
routes, including drone operations, are being evaluated for expansion in future stages.

Go2Delivery
Partnership

On
May 20, 2025, we announced a partnership with Go2 Delivery, a Virginia-based courier, to autonomously deliver high-risk, high-value specialty
pharmacy products using Arrive AI technology. Go2 Delivery is rolling out Arrive Points initially in Virginia Beach, Virginia. The companies
have been testing the process for several months, with the initial units delivered in 2024. We recognized revenue this quarter from the
installation of the units and began subscription revenue service in April 2025.

Patents
Issued

On
June 10, 2025, we announced the issuance of a new U.S. patent. The new patent (US12304671B2) is for the Arrive Points’ ability to heat
and cool items on demand and brings our total issued U.S. patents to eight.

Skye Air Mobility Partnership

On June 24, 2025, we announced a new global customer, Skye Air Mobility. Skye Air is India’s dominant and rapidly
expanding hyperlocal drone delivery platform, making about 6,000 deliveries per day. Under the terms of the agreement, the two companies
will collaborate to deploy up to 500 Arrive Points in India, including the capital of New Delhi. The first Arrive Point units are expected
to be delivered to Skye Air by the end of 2025.

Filing
of S-8 Registration Statement 

On
June 13, 2025, we filed a registration statement on Form S-8 to register 1,500,000 shares of common stock, which includes (i) 886,799
shares which may be issued under the Company’s 2023 Equity Incentive Plan (the “2023 Plan”), and (ii) 613,201 shares
that may be issued upon exercise of outstanding options granted under the 2023 Plan. The 2023 Plan was adopted by